National registry study on adult pulmonary Langerhans cell histiocytosis
Enquête épidémiologique Sur la prévalence et le Pronostic de l'Histiocytose Langerhansienne Pulmonaire de l'Adulte en France
This study looks at the long-term health and survival of adults with pulmonary Langerhans cell histiocytosis to see what factors might affect their outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Trial ID | NCT04665674 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the long-term outcomes, particularly survival, of adult patients diagnosed with pulmonary Langerhans cell histiocytosis (PLCH). It is the first prospective cohort study in this field, utilizing a nationwide registry in France to gather data from a large cohort of PLCH patients. Participants will be followed over an extended period to identify risk factors that influence long-term outcomes. The study will rely on standard care interventions while focusing on observational data collection.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 years and older with a confirmed diagnosis of pulmonary Langerhans cell histiocytosis.
Not a fit: Patients with alternative diagnoses or those under 18 years of age may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the long-term prognosis and management of patients with pulmonary Langerhans cell histiocytosis.
How similar studies have performed: This study is novel as it is the first prospective evaluation of long-term outcomes in PLCH patients, and similar studies in other histiocytosis conditions have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>= 18 years * Diagnosis of PLCH was either histologically confirmed on a biopsy of an involved tissue, or based on the combination of the following criteria: 1) an appropriate clinical picture; 2) a typical nodulo-cystic pattern on lung high-resolution computed tomography (HRCT) and 3) exclusion of alternative diagnoses Exclusion Criteria: \-
Where this trial is running
Paris
- French national reference centre for Histiocytoses — Paris, France (Recruiting)
Study contacts
- Study coordinator: Abdellatif TAZI, MD PhD
- Email: abdellatif.tazi@aphp.fr
- Phone: 142499198
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.